The Value Of Immunohistochemistry Classification On Prognosis Of Diffuse Large B-Cell Lymphoma

ObjectiveTo study the prognosis and response to the chemotherapy of germinal centerB-cell-like (GCB) and non-germinal center B-cell-like(non-GCB) Diffuse large B-celllymphoma (DLBCL) restrospectively.MethodWe selected 53 DLBCL cases in our hospital since 2005.Immunohistochemistry technique ( ElivisionTM plus method) was used to assess the expression levels of CD5, bcl-6, CD10, Mum-1 protein in these specimens. DLBCL wasclassified as GCB and non-GCB and CD5+ by The new 2008 WHO classification.ResultGCB group, non-GCB group and CD5+ group is found in 41.5% (22/53),52.8%(28/53),5.7% ( 3/53 ) cases, respectively. Non-GCB patients had higher international prognostic index(IPI) score of 3-5(67.9%).The 3-year overall survival(OS) for the GCB group was 71.4% compared with only 48.1% for the non-GCB group (P =0.004). Compared with non-GCB group,GCB group had a longer progress-free survival(P=0.008).Received CHOP the overall response rate (ORR) of GCB group and non-GCB group is 88.2% and 35.7% respectively(P=0.002). The ORR is no differences between the two groups treated by R-CHOP. Non-GCB group received R-CHOP compared with CHOP had no difference ORR ,3-year OS and PFS.ConclusionIn summary, The GCB group has a significantly better survival than non-GCBgroup. The non-GCB group do not have a better survival after received R-CHOP.